Image 1-Taltz - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Taltz (ixekizumab) for the Treatment of Non-Radiographic Axial Spondyloarthritis

Image 1-Taltz
Taltz® (ixekizumab) is the first and the only IL-17A antagonist therapy for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). Credit: Eli Lilly.